These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 25823735)

  • 1. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.
    Huntington SF; Svoboda J; Doshi JA
    J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance.
    Suh KJ; Kim KH; Kim R; Byun JM; Kim M; Park JH; Keam B; Kim TM; Kim JS; Choi IS; Heo DS
    Korean J Intern Med; 2019 Jul; 34(4):894-901. PubMed ID: 29466847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
    van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
    Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
    Guadagnolo BA; Punglia RS; Kuntz KM; Mauch PM; Ng AK
    J Clin Oncol; 2006 Sep; 24(25):4116-22. PubMed ID: 16943528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Routine Magnetic Resonance Imaging in the Follow-Up of Patients With Nasopharyngeal Carcinoma After Intensity Modulated Radiation Therapy.
    Zhou GQ; Wu CF; Zhang J; Mao YP; Tang LL; Chen L; Guo R; Ma J; Sun Y
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1382-1391. PubMed ID: 29804816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating PET-CT in routine surveillance and follow-up after treatment for cervical cancer: a cost-effectiveness analysis.
    Auguste P; Barton P; Meads C; Davenport C; Małysiak S; Kowalska M; Zapalska A; Guest P; Martin-Hirsch P; Borowiack E; Khan K; Sundar S; Roberts T
    BJOG; 2014 Mar; 121(4):464-76. PubMed ID: 24299112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
    Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
    Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling.
    Meads C; Auguste P; Davenport C; Małysiak S; Sundar S; Kowalska M; Zapalska A; Guest P; Thangaratinam S; Martin-Hirsch P; Borowiack E; Barton P; Roberts T; Khan K
    Health Technol Assess; 2013 Mar; 17(12):1-323. PubMed ID: 23537558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [18FDG-PET/CT cost-effectiveness compared to CT at the end of treatment in pediatric Hodgkin's lymphoma patients].
    García-Molina M; Chicaíza-Becerra L; Moreno-Calderon A; Prieto-Martínez V; Sarmiento-Urbina I; Linares-Ballesteros A
    Rev Salud Publica (Bogota); 2014; 16(2):260-9. PubMed ID: 25383499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of PET and PET/computed tomography: a systematic review.
    Gerke O; Hermansson R; Hess S; Schifter S; Vach W; Høilund-Carlsen PF
    PET Clin; 2015 Jan; 10(1):105-24. PubMed ID: 25455883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma?
    Hayashi K; Abe K; Yano F; Watanabe S; Iwasaki Y; Kosuda S
    Ann Nucl Med; 2005 Jul; 19(5):393-8. PubMed ID: 16164196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic evaluation of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
    Auguste P; Barton P; Hyde C; Roberts TE
    Health Technol Assess; 2011 Apr; 15(18):iii-iv, 1-54. PubMed ID: 21524363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass.
    Dann EJ; Berkahn L; Mashiach T; Frumer M; Agur A; McDiarmid B; Bar-Shalom R; Paltiel O; Goldschmidt N
    Br J Haematol; 2014 Mar; 164(5):694-700. PubMed ID: 24313286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules.
    Gould MK; Sanders GD; Barnett PG; Rydzak CE; Maclean CC; McClellan MB; Owens DK
    Ann Intern Med; 2003 May; 138(9):724-35. PubMed ID: 12729427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of strategies introducing integrated ¹⁸F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer.
    Han Y; Xiao H; Zhou Z; Yuan M; Zeng Y; Wu H; Fang Y
    Nucl Med Commun; 2015 Mar; 36(3):234-41. PubMed ID: 25460305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma.
    Krug B; Crott R; Roch I; Lonneux M; Beguin C; Baurain JF; Pirson AS; Vander Borght T
    Acta Oncol; 2010; 49(2):192-200. PubMed ID: 20059314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.
    González-Barca E; Canales M; Cortés M; Vidal MJ; Salar A; Oriol A; Bargay J; Bello JL; Sánchez JJ; Tomás JF; Donato E; Ferrer S; Caballero D;
    Nucl Med Commun; 2013 Oct; 34(10):946-52. PubMed ID: 23880897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the use of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the workup of Staphylococcus aureus bacteraemia: a cost-utility analysis.
    Ong SWX; Zhabokritsky A; Daneman N; Tong SYC; Wijeysundera HC
    Clin Microbiol Infect; 2023 Nov; 29(11):1417-1423. PubMed ID: 37353076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
    Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
    J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.